Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
SOLUtion Medical is a specialty pharmaceutical company developing reconstitution drug-delivery products, including its dual-chamber TwistJECT prefilled syringe and auto-injector for treating adrenal crisis. It aims to build a platform serving patients, caregivers, and clinicians, with a pipeline targeting additional indications such as mental health and fertility.
4 investors
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease. Its lead program, clofutriben, is an HSD-1 inhibitor being evaluated in a Phase 2b trial for patients with inadequately controlled type 2 diabetes driven by elevated cortisol.
4 investors
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.
4 investors
Spore.Bio develops real-time microbial detection technology for industrial quality control, replacing traditional Petri dish culture methods used in factory settings. It combines photonics, AI, and biology to detect, quantify, and identify living microorganisms without reagents or culturing.
4 investors
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients. The company was founded by cancer biology researchers and focuses on discovering and developing precision cancer medicines.
4 investors
Strateos operates a cloud lab platform offering high-throughput laboratory automation as a service, letting scientists design, run, and analyze experiments remotely through a web browser. It serves pharma, biotech, startups, academia, CROs, and AI drug discovery teams in the life sciences.
4 investors
Sudo Biosciences discovers and develops small-molecule medicines, including next-generation TYK2 inhibitors, for serious neurological and immunological conditions such as multiple sclerosis and immune-mediated inflammatory diseases. It focuses on medicinal chemistry, translational biology, and patient-centered drug development.
4 investors
SymBio Pharmaceuticals develops and delivers prescription pharmaceuticals, providing product information on its medical drugs to healthcare professionals in Japan.
4 investors
4 investors
Syntis Bio develops oral therapies that use the biology of the small intestine to treat conditions ranging from rare genetic disorders to common diseases. The company is advancing a pipeline of drug candidates across multiple therapeutic areas, beginning with obesity.
4 investors
T-Cypher develops drugs against novel disease-specific targets to treat patients with cancer and autoimmune diseases, focusing on immune-system-engaging medicines. Its approach combines proprietary wet-lab and computational platforms to study cellular communication and identify new therapeutic targets.
4 investors
T-knife develops engineered T cell therapies designed to treat patients with solid tumors, using proprietary platforms and synthetic biology to enhance T cells. Its lead candidate, TK-6302, targets the PRAME tumor antigen, with a Phase 1 trial planned to begin in 2026.
4 investors
Tahoe Bio AI applies machine learning and computational biology to drug discovery and development. The company leverages AI and advanced cellular modeling for pre-clinical research in the biotech industry.
4 investors
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors. The company focuses on expanding access to precision cancer therapies for patients.
4 investors
Taxa develops probiotic skincare products that target the skin microbiome, including a single-application deodorant cream that lasts one week. The company makes shelf-stable probiotic creams using natural ingredients such as mango butter and sunflower extract.
4 investors
4 investors
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.
4 investors
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program. As of May 5, 2026, it operates as a subsidiary of Merck & Co., Inc. (known as MSD outside the US and Canada).
4 investors
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse. The company has advanced two internally generated immunotherapies into clinical trials and maintains a strategic alliance with Gilead Sciences.
4 investors
4 investors
Trace Genomics, now part of Miraterra, provides soil analysis and genomic sequencing to give growers and agronomists insights on nutrients and pathogens across more than 70 crops and 225+ pathogens. Its TraceCOMPLETE product portfolio (including TracePHOS, TraceN, TraceCHEM, and TraceCARBON) supports seed selection, treatment, and soil management decisions in agriculture.
4 investors
Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers. It focuses on oncology and immunotherapy drug development.
4 investors
Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument. It targets routine blood testing for consumers as an alternative to traditional off-site labs, pursuing a staged FDA clearance strategy for its assays.
4 investors
A company focused on developing clinical treatments aimed at improving patient outcomes.
4 investors